JC04 Rec'd PCT/PTO 26 SEP 2005

E FORM I	_	J'	M41100 a ·								
FORM I	TO-1390(modified) U.S. DEPARTMENT OF COMM 0-95)	IERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 30667								
	TRANSMITTAL LETTER TO	LIC ADDITION NO (IE VNOVAD SEE 27 CED									
DES	SIGNATED/ELECTED OFFICE	U.S. APPLICATION NO. (IF KNOWN), SEE 37 CFR									
A FILING UNDER 35 U.S.C., 371			10/550681								
INTE	RNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED								
	PCT/IL2004/000279	25 March 2004	27 March 2003								
TITLE OF INVENTION PHARMACEUTICAL COMPOSITIONS FOR INHIBITING METAL ION DEPENDENT ENZYMATIC											
r		Y AND METHODS FOR THE US									
APPL	ICANT(S) FOR DO/EO/US										
	·	Jerachmiel (Yori) APPELBAU	·								
Appli	cant herewith submits to the United Sta	ates Designated/Elected Office (DO/EO.	US) the following items and other information:								
 1. 区	This is a FIRST submission of items	concerning a filing under 35 U.S.C. 371	1								
2.		T submission of items concerning a filing									
;		ational examination procedures (35 U.S.	_								
		the applicable time limit set in 35 U.S.C									
4. 🗖	A proper Demand for International Pr	eliminary Examination was made by the	19 th month from the earliest claimed priority date.								
5. 🗷	A copy of the International Applicati										
		ired only if not transmitted by the Intern	national Bureau).								
	b. E has been transmitted by the International Bureau.										
	c. \square is not required, as the application was filed in the United States Receiving Office (RO/US).										
	A translation of the International Application into English (35 U.S.C. 371(3)(2). A copy of the International Search Report (PCT/ISA/210).										
	= = -	ernational Application under PCT Article	e 19 (35 U.S.C. 371(c)(3)								
ů. –		uired only if not transmitted by the Inter									
	b. \square have been transmitted by the	·	· · · · · · · · · · · · · · · · · · ·								
	-	r, the time limit for making such amend	ments has NOT expired.								
	d. have not been made and will not be made.										
9. A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)).											
10. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).											
		ry Examination Report (PCT/IPEA/409									
12. 🗀	A translation of the annexes to the In	ternational Preliminary Examination Re	port under PCT Article 36 (35 U.S.C. 371(c)5)).								
	13 to 18 below concern document(s)										
	An Information Disclosure Statement										
	4. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
15. 🗀	A FIRST preliminary amendment.	12									
A SECOND or SUBSEQUENT preliminary amendment.											
 16. □ A substitute specification. 17. □ A change of power of attorney and/or address letter. 											
	Certificate of Mailing by Express Ma										
	19. The sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc)										
sequence listing											
20. Other items or information: PCT REQUEST; PRELIMINARY AMENDMENT											
21. 🗵 30 pages of specification (including Abstract page)											
	7 sheets of drawings										
	pages of sequence listing										
24. ☑ <u>37</u> total pages											

JC20 Rec'd PCT/PTO 2 6 SEP 2005

V.S. APPLICATION NO. (IF KNOWN), See 37 CFR

INTERNATIONAL APPLICATION NO. PCT/IL2004/000279

ATTORNEY'S DOCKET NUMBER

30667

THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

FOR:	Column 1 No. FILED	Column 2 No. EXTRA	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
			RATE	FEE	RATE	FEE
Basic National Stage Fee				\$ 150		\$ 300
National Stage Search Fee				\$ 250		\$ 500
National Stage Examination Fee				\$ 100		\$ 200
National Stage Application Size Fee (Per 50 Pages Over 100)			x \$ 125	\$	x \$250	\$
Multiple Dependent Claim			x \$ 180	\$	x \$ 360	\$
Total Claims*	33 - 20=	13	x \$ 25	\$ 325	x \$50	\$
Independent Claims*	173=	14	x \$100	\$ 1400	x \$200	\$
* (If the difference in Column 1 is less than "0", enter "0" in Column 2)			TOTAL	\$2225	TOTAL	<u>\$</u>

- Please charge my deposit account No. 50-1407 in the amount of \$2225.

 A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No 50-1407. A duplicate copy of this sheet is enclosed.
 - Any additional filing fees required under 37 CFR 1.16.
 - Any patent application processing fees under 37 CFR 1.17.
- The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to deposit Account No. 50-1407. A duplicate copy of this sheet is enclosed.
 - Any patent application processing fees under 37 CFR 1.17.
 - Any filing fees under 37 CFR 1.16 for presentation of extra claims.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Martin Moynihan PRTSI, Inc. P.O. Box 16446 Arlington, Virginia 22215 USA

Tel: (703) 598-7851 Fax: (703) 415-4864

Martin	Z!	Ma	mik	an
SIGNATURE		,		

Martin Moynihan NAME

40,338

REGISTRATION NUMBER

22 September 2005_ DATE